FDA granted accelerated approval to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy.
What this means
Trutakna is a lab-made protein that calms overactive immune cells by blocking two signals that drive kidney damage in IgA nephropathy. The FDA granted accelerated approval based on early data showing it may slow kidney decline, with full approval pending confirmatory trials. This gives patients with the rare kidney disease their first targeted treatment option while Vera completes larger studies to prove long-term benefits.
